[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multi-vessel-coronary-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multi-vessel-coronary-artery-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,77,103,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100436864","timing-of-ffr-guided-pci-for-non-ira-in-nstemi-and-mvd-option-nstemi-100436864",false,"NCT04968808","Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)","OPtimal TIming of Fractional Flow Reserve-Guided Complete RevascularizatiON in Non-ST-Segment Elevation Myocardial Infarction (OPTION-NSTEMI)","Inclusion Criteria:\n\n1. Age ≥ 19 years old\n2. Non-ST-segment elevation myocardial infarction\n\n   * Angina pectoris or equivalent ischemic chest discomfort with at least 1 of 3 features and,\n\n     * occurs at rest, usually lasting \\> 10 minutes\n     * severe and new onset (within the prior 4-6 weeks)\n     * crescendo pattern\n   * Elevated cardiac biomarkers and,\n\n     * ≥ 99% value of high-sensitivity cardiac troponin\n   * No ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads or newly developed left bundle branch block on 12-lead electrocardiogram\n3. PCI within 72 hours after symptom development\n4. Multivessel disease: Non-IRA with at least 2.5 mm diameter and 50% diameter stenosis by visual estimation\n5. Patient's or protector's agreement about study design and the risk of PCI\n\nExclusion Criteria:\n\n1. Cardiogenic shock at initial presentation or after treatment of IRA\n2. TIMI flow at non-IRA ≤ 2\n3. Severe procedural complications (e.g. persistent no-reflow phenomenon, coronary artery perforation) which restricts study enrollment by operators' decision\n4. Non-IRA lesion not suitable for PCI treatment by operators' decision\n5. Chronic total occlusion at non-IRA\n6. History of anaphylaxis to contrast agent\n7. Pregnancy and lactation\n8. Life expectancy \\\u003C 1-year\n9. Severe valvular disease\n10. History of CABG, or planned CABG\n11. Fibrinolysis before admission","ALL","19 Years",{"count":19,"type":20},1014,"ESTIMATED","INTERVENTIONAL",[23],"NA","Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD. Therefore, we planned to perform prospective, open-label, randomized trial to evaluate the efficacy and safety of immediate complete revascularization (percutaneous coronary intervention \\[PCI\\] for both infarct-related artery \\[IRA\\] and non-IRA during index PCI) compared to staged PCI strategy of non-IRA (PCI for IRA followed by non-IRA PCI after several days). PCI procedure at non-IRA with diameter stenosis between 50 and 69% should be conducted with the aid of fractional flow reserve (FFR), and non-IRA with diameter stenosis ≥ 70% will be revascularized without FFR.",[26,27,28],"Myocardial Infarction, Acute","Multi-Vessel Coronary Artery Stenosis","Multi Vessel Coronary Artery Disease",[30,31,27,32,33,34,35,36,37,38],"Non-ST-Segment Elevation Myocardial Infarction","Multi-Vessel Coronary Artery Disease","Culprit-Only","Multi-Vessel Percutaneous Coronary Intervention","Percutaneous Coronary Intervention","Complete Revascularization","Timing","Staged Percutaneous Coronary Intervention","Fractional Flow Reserve","RECRUITING","2026-04-22",{"date":42,"type":43},"2026-04-27","ACTUAL",{"date":45,"type":43},"2021-09-01",{"date":47,"type":20},"2028-08-31",{"name":49,"class":50},"Chonnam National University Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100634410","clinical-impact-of-dcb-based-versus-des-based-intervention-in-patients-with-mvcad-100634410","NCT07539324","Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD","Clinical Impact of Drug-Coated-Balloon-based Versus Drug-Eluting-Stent-based Intervention in Patients With Multivessel Coronary Artery Disease : A Prospective, Multicenter, Active-controlled, Randomized, Single-blind, Investigator-initiated Clinical Trial","DCBMultivessel","Inclusion Criteria:\n\n1. Male or female adults aged 20 years or older with stable angina, silent myocardial ischemia, unstable angina, or non-ST-segment elevation myocardial infarction (NSTEMI).\n2. In cases of ST-segment elevation myocardial infarction (STEMI), patients who have undergone successful primary percutaneous coronary intervention (PCI) without complications, at least 48 hours post-procedure, and whose target lesion(s) show no evidence of thrombus.\n3. Patients with multivessel coronary artery disease, defined as angiographic stenosis of 50% in at least two major epicardial coronary arteries requiring PCI as determined by the investigator.\n4. Reference vessel diameter (RVD) of the target lesion(s) between 2.25 mm and 4.0 mm by visual estimation or quantitative coronary angiography (QCA).\n5. Target lesions suitable for treatment with either drug-eluting stents (DES) or drug-coated balloons (DCB).\n6. Patients who have voluntarily provided written informed consent and are willing and able to comply with all protocol-specified requirements.\n\nExclusion Criteria:\n\n1. Cardiogenic shock or patients requiring mechanical or pharmacological circulatory support.\n2. Patients with a life expectancy of less than 2 years due to comorbid conditions.\n3. Patients who are currently participating or planning to participate in other interventional clinical trials, excluding observational studies.\n4. Women who are pregnant or have childbearing potential.\n5. Patients with a known hypersensitivity or allergy to contrast media, L-605 Cobalt-Chromium (Co-Cr) alloy, PLA and PLGA polymers, shellac, Vitamin E-TPGS, paclitaxel, or sirolimus.\n6. Patients with a target lesion located within a saphenous vein graft (SVG) or an arterial graft.\n7. Patients with target vessels\u002Flesions that are excessively tortuous, angulated, or severely calcified, such that pre-dilatation cannot be performed or has failed, making the application of the investigational medical device difficult.","20 Years",{"count":62,"type":20},892,[23],"This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with multivessel coronary artery lesions measuring 2.25 mm to 4.0 mm in diameter through a prospective, multicenter, active-controlled, randomized, investigator-initiated clinical trial.",[28,34],"NOT_YET_RECRUITING","2026-04-13",{"date":69,"type":43},"2026-04-20",{"date":71,"type":20},"2026-04-15",{"date":73,"type":20},"2032-07-31",{"name":75,"class":76},"Genoss Co., Ltd.","INDUSTRY",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":51},"100479802","phase-4-revascularization-strategy-of-multivessel-disease-for-patients-with-acute-myocardial-infarction-complicated-by-cardiogenic-shock-undergoing-veno-arterial-extracorporeal-membrane-oxygenator-100479802","NCT05527717","Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator","REvaSCUlarization StratEgy of Multivessel Coronary Artery Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic SHOCK Undergoing Veno-arterial Extracorporeal Membrane Oxygenator: Randomized-Controlled Trial (RESCUE-SHOCK)","RESCUE-SHOCK","Inclusion Criteria:\n\n* Subject must be at least 19 years of age\n* Patients presented with AMI (ST-segment elevation MI \\[STEMI\\] or non-ST-segment elevation MI \\[NSTEMI\\]) complicated by CS (SCAI Shock classification C, D or E) who requiring VA-ECMO.\n* Target lesions amenable for planned primary PCI by operators' decision\n* Patients with multi-vessel disease\n\nExclusion Criteria:\n\n* Other causes of shock (hypovolemia, sepsis, obstructive shock).\n* Shock due to mechanical complication to MI (rupture of papillary muscle, the ventricular septum, or free wall).\n* Unwitnessed out of hospital cardiac arrest with persistent Glasgow coma scale \\\u003C8 after the return of spontaneous circulation.\n* Patients with single-vessel disease (Patients with single-vessel disease will be enrolled in the RESCUE-SHOCK registry)\n* Onset of shock \\>24 hours.\n* Known heparin intolerance.\n* Other severe concomitant disease with limited life expectancy \\\u003C 6 months\n* Pregnancy or breast feeding\n* Do not resuscitate wish",{"count":86,"type":20},560,[88],"PHASE4","This study is a prospective, open-label, two-arm, randomized multicenter trial to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with an advanced form of CS patients who require veno-arterial extracorporeal membrane oxygenator (VA-ECMO).",[91,92,28,93],"Cardiogenic Shock","Acute Myocardial Infarction","Extracorporeal Membrane Oxygenation","2024-11-04",{"date":96,"type":43},"2024-11-06",{"date":98,"type":43},"2022-11-16",{"date":100,"type":20},"2028-12-31",{"name":102,"class":50},"Samsung Medical Center",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":113,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":51},"100524078","practice-change-with-drug-coated-balloon-in-patients-with-multivessel-coronary-artery-disease-100524078","NCT06104033","Practice Change With Drug-coated Balloon in Patients With multiVessel Coronary Artery Disease","DCB-MVD","Inclusion Criteria:\n\n1. Age 19 or older\n2. Multivessel coronary artery disease patients requiring coronary intervention\n\n   * Stenosis of 2 or more major coronary arteries or major coronary artery branches (Vessel size ≥2.5mm) with diameter stenosis ≥50% or fractional flow reserve ≤0.80 requiring repeat revascularization\n   * Having stenotic lesions requiring revascularization with a vessel size of 2.5mm to 3.0mm\n3. Capable of understanding the risks and benefits of participating in the study and providing informed consent\n\nExclusion Criteria:\n\n1. Incapable of voluntarily providing informed consent\n2. Allergy or contraindication to aspirin, P2Y12 inhibitors, or components of drug-eluting stents\n3. Cardiogenic shock or cardiac arrest patients\n4. Patients with severe left ventricular systolic dysfunction (ejection fraction \\\u003C30%)\n5. Patients for whom coronary artery bypass surgery is prioritized over coronary artery intervention\n6. Patients with severe valvular heart disease requiring open heart surgery\n7. Pregnant or lactating women","100 Years",{"count":112,"type":20},500,"1 Year","OBSERVATIONAL","This study is a prospective, multicenter, open-label, observational study to investigate the impact of using drug-coated balloons (DCBs) in the treatment of coronary artery lesions in patients with multivessel coronary artery disease (MVD), as opposed to the default strategy of using only drug-eluting stents (DES). The investigators aim to assess changes in clinical practice towards a hybrid treatment strategy (DES and DCB) and its effects on clinical outcomes.",[117,28],"Coronary Artery Disease",[119,120,121,122,123],"Coronary artery disease","Multivessel coronary artery disease","Percutaneous coronary intervention","Drug-coated balloon","Drug-eluting stent","2023-10-23",{"date":126,"type":43},"2023-10-27",{"date":128,"type":43},"2023-09-18",{"date":130,"type":20},"2026-10-31",{"name":132,"class":50},"Bon-Kwon Koo",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":51},"100456965","prospective-evaluation-of-complete-revascularization-in-patients-with-multivessel-disease-excluding-chronic-total-occlusions-100456965","NCT05230446","PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions","PRESENT","Inclusion Criteria:\n\n1. Age ≥ 18 years, ≤85 years\n2. The patient is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's Instructions for Use and the Declaration of Helsinki\n3. Patient indication, lesion length and vessel diameter of the target lesion(s) are according to the 'Instructions for Use' that comes with every Resolute Onyx (Zotarolimus-Eluting stent) system.\n4. The patient is willing and able to cooperate with study procedures and required follow up visits\n5. The subject or legal representative has been informed of the nature of the study and agrees to its provisions and has provided an EC approved written informed consent, including data privacy authorization\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years and \\> 85 years.\n2. Single coronary vessel disease.\n3. No left anterior descending lesion.\n4. Patients in cardiogenic shock.\n5. Patients with STEMI.\n6. Presence of a chronic total occlusion (CTO) defined as coronary lesion with Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 on initial angiography present for more than or equal to 3 months.\n7. Left main coronary artery disease\n8. Patients who cannot give informed consent or have a life expectancy of less than 12 months.\n9. Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to any of the study medications, including both aspirin and P2Y12 inhibitors.\n10. Patients with an extreme LAD tortuosity imparing OCT catheter advancement\n11. Enrollment in another study with another investigational device or drug trial that has not reached the primary endpoint. The patient may only be enrolled once in the PRESENT study.\n12. Previous coronary artery bypass grafting (CABG).\n13. Patient requiring additional cardiac surgery within 6 months.\n14. Women of childbearing potential who do not have a negative pregnancy test result within 7 days before the procedure, women who are known to be pregnant, or who are breastfeeding.","18 Years","85 Years",{"count":143,"type":20},609,[23],"This prospective, multicenter, non-randomized, single arm, objective performance goal (OPG) study is designed to evaluate clinical outcomes after complete revascularization by PCI and imaging guidance (OCT) in patients with multivessel coronary artery disease including left anterior descending (LAD) presenting with stable angina, or documented silent ischemia, or non-ST segment elevation acute coronary syndrome (NSTE-ACS).",[28,147,148,149,117,34,150],"Non-ST Elevation Myocardial Infarction","Unstable Angina","Stable Angina","Optical Coherence Tomography","2022-01-25",{"date":153,"type":43},"2022-02-09",{"date":155,"type":43},"2021-11-18",{"date":157,"type":20},"2027-11-18",{"name":159,"class":50},"Erasmus Medical Center"]